BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 20212251)

  • 21. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).
    Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dmoszyńska A; Wojtaszko M; Skotnicki AB; Nowak W; Hellmann A; Lewandowski K; Zdziarska B; Konopka L; Ceglarek B; Dwilewicz-Trojaczek J; Boguradzki P; Kuliczkowski K; Sułek K; Warzocha K
    Med Sci Monit; 2005 Oct; 11(10):PI71-9. PubMed ID: 16192912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
    Giles FJ; Shi GG; Cortes JE; Thomas D; Keating AR; Kantarjian HM; Keating MJ; O'Brien SM
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):223-8. PubMed ID: 12783199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
    J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
    Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
    Kalinka-Warzocha E; Wajs J; Lech-Maranda E; Ceglarek B; Holowiecki J; Federowicz I; Walewski J; Czyz J; Robak T; Warzocha K;
    Cancer; 2008 Jul; 113(2):367-75. PubMed ID: 18470902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
    Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
    Holowiecki J; Grosicki S; Giebel S; Robak T; Kyrcz-Krzemien S; Kuliczkowski K; Skotnicki AB; Hellmann A; Sulek K; Dmoszynska A; Kloczko J; Jedrzejczak WW; Zdziarska B; Warzocha K; Zawilska K; Komarnicki M; Kielbinski M; Piatkowska-Jakubas B; Wierzbowska A; Wach M; Haus O
    J Clin Oncol; 2012 Jul; 30(20):2441-8. PubMed ID: 22508825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
    J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
    Forconi F; Fabbri A; Lenoci M; Sozzi E; Gozzetti A; Tassi M; Raspadori D; Lauria F
    Hematol Oncol; 2008 Dec; 26(4):247-51. PubMed ID: 18642397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.